<DOC>
	<DOCNO>NCT02422706</DOCNO>
	<brief_summary>Current Helicobacter Pylori infection prefer treatment involves ; proton pump inhibitor ( PPI ) -based triple qudrable regimen . Omeprazole , Amoxicillin , Clarithromycin one global standard care confirm H.pylori infection . Metronidazole ( MTZ ) use instead Amoxicillin Clarithromycin case allergy resistance . However , recent study base Maastricht III guideline , indicated treatment PPI-based triple regimen first-line therapy fail ~30 % patient intention-to-treat ( ITT ) basis , fail ~ 50 % patient treat PPI-based triple regimen Metronidazole . This treatment resistance also issue warrant investigation agent . Helicobacter pylori infection become increasingly resistant traditional first-line treatment regimen emerge antibiotic resistance couple poor patient compliance complete treatment course decrease H. pylori eradication rate . So considerable interest evaluate new antibiotic combination regimen .</brief_summary>
	<brief_title>Study Nitazoxanide ( NTZ ) Based New Therapeutic Regimens Helicobacter Pylori</brief_title>
	<detailed_description>Helicobacter pylorus ( H.pylori ) small , Gram-negative spirochete inhabit mucous layer overlie gastric epithelial cell human . It common prevalent chronic human bacterial infection common cause gastritis worldwide ; . Furthermore , accord World Health Organization , HP classify type 1 carcinogen primary cause peptic ulcer disease , gastric carcinoma , mucosa-associated lymphoid tissue lymphoma . Current Helicobacter Pylori infection prefer treatment involves ; proton pump inhibitor ( PPI ) -based triple qudrable regimens.Omeprazole , Amoxicillin &amp; Clarithromycin one global standard care confirm H.pylori infection .Metronidazole ( MTZ ) use instead Amoxicillin Clarithromycin case allergy resistance . However , study Rokkas , et al. , 2008 base Maastricht III guideline , indicated treatment PPI-based triple regimen first-line therapy fail ~30 % patient intention-to-treat ( ITT ) basis , fail ~ 50 % patient treat PPI-based triple regimen Metronidazole.This treatment resistance also issue warrant investigation agent . Helicobacter pylori infection become increasingly resistant traditional first-line treatment regimen emerge antibiotic resistance couple poor patient compliance complete treatment course decrease H. pylori eradication rate .So considerable interest evaluate new antibiotic combination regimen . Nitazoxanide ( NTZ ) antibiotic microbiological characteristic similar Metronidazole sittled therapy intestinal protozoa helminthic infection , study additional therapy Peg Interferon Ribavirin chronic hepatitis C virus ( HCV ) . In last year Nitazoxanide evaluate single agent therapy H. Pylori infection show controversed results.. However ( NTZ ) base regimen recently study show interesting result without apparent problem resistance Metronidazole nearby cost.Moreover ; Levofloxacin , PPI , NTZ &amp; Doxycycline ( LOAD ) regimen good result H.pylori infection ~90 % cure rate..But uptil actual similar report trial Egypt .</detailed_description>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Consecutive patient dyspeptic symptom undergo upper Gastointestinal tract ( GIT ) endoscopy select HP infect patient recruit study . Patients must Helicobacter Pylori induce disease confirm endoscopy HP monoclonal stool antigen . 1 . Previous gastric duedenal operation malignancy . 2 . Active GIT bleeding . 3 . Pregnancy . 4 . Previous treatment HP . 5 . Current use Antiacids ( proton pump inhibitor ( PPI ) , H2 receptor antagonist ) , anticoagulant , recent use antibiotic ( within 6 week ) . 6 . Allergy medication include study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>